N (%) | |
---|---|
Breast cancer type | 197 (100.0%) |
TNBC | 119 (60.4%) |
Non-TNBC | 78 (39.6%) |
Histopathology | 197 (100.0%) |
Ductal | 176 (89.3%) |
Lobular | 4 (2.0%) |
Medullary | 10 (5.1%) |
Tubular | 2 (1.0%) |
Other | 5 (2.5%) |
Histopathological grade | 197 (100.0%) |
Grade 1 | 5 (2.5%) |
Grade 2 | 42 (21.3%) |
Grade 3 | 150 (76.1%) |
ER status | 197 (100.0%) |
Negative (0%) | 119 (60.4%) |
Weak (1–9%) | 0 (0.0%) |
Moderate (10–59%) | 14 (7.1%) |
High (> 59%) | 64 (32.5%) |
PR status | 197 (100.0%) |
Negative (0%) | 119 (60.4%) |
Weak (1–9%) | 0 (0.0%) |
Moderate (10–59%) | 31 (15.7%) |
High (> 59%) | 47 (23.9%) |
Ki67 status | 197 (100.0%) |
Negative (< 5%) | 11 (5.6%) |
Weak (5–14%) | 29 (14.7%) |
Moderate (15–30%) | 37 (18.8%) |
High (> 30%) | 64 (32.5%) |
Missing | 56 (28.4%) |
T class | 197 (100.0%) |
T1 | 88 (44.7%) |
T2 | 97 (49.2%) |
T3 | 9 (4.6%) |
T4 | 3 (1.5%) |
N class | 197 (100.0%) |
N0 | 108 (54.8%) |
N1 | 66 (33.5%) |
N2 | 17 (8.6%) |
N3 | 6 (3.0%) |
M class | 197 (100.0%) |
M0 | 197 (100.0%) |
Local relapse | 197 (100.0%) |
No local relapse | 182 (92.4%) |
Local relapse | 15 (7.6%) |
Distant metastases | 197 (100.0%) |
No distant metastases | 145 (73.6%) |
Distant metastases | 52 (26.4%) |